Core Viewpoint - Hanmi Pharmaceutical is advancing its GLP-1/GIP/GCG tri-target receptor agonist HM15275 for obesity treatment, with a Phase II clinical trial registered in the U.S. set to recruit 250 participants and expected to complete by January 2027 [2][3][4]. Group 1 - The Phase II trial aims to evaluate weight loss after 36 weeks of treatment [3]. - HM15275 is designed to enhance weight loss and metabolic improvement by simultaneously activating GLP-1, GIP, and glucagon (GCG) receptors [4]. - Hanmi has also licensed its GLP-1/GCG dual-target candidate to Merck, which is currently in Phase II clinical trials, indicating the company's ongoing investment and strategic positioning in the global obesity treatment market [5]. Group 2 - The "GLP-1 Club" has established a network of hundreds of professionals, providing a platform for industry insights and discussions related to the GLP-1 drug development [8]. - The article mentions various GLP-1 drugs, including semaglutide, tirzepatide, and others, highlighting the growing interest and development in this therapeutic area [13]. - GLP-1 is a hormone produced by intestinal L cells, functioning as an incretin that enhances insulin secretion and reduces appetite, thereby aiding in blood sugar control and weight loss [13].